TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics
Brief Summary: The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.


Options:
A: Arm Label: D-cycloserine plus CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cycloserine, Behavioral: CBT | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo pill, Behavioral: CBT | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus CBT | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Placebo pill | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): D-cycloserine plus CBT, Placebo pill
B: Arm Label: D-cycloserine plus exposure therapy; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine, Behavioral: Exposure therapy | Arm Label: Placebo plus exposure therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Exposure therapy, Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus exposure therapy | Intervention Type: BEHAVIORAL; Name: Exposure therapy; Assigned to Arm(s): D-cycloserine plus exposure therapy, Placebo plus exposure therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus exposure therapy
C: Arm Label: Cognitive Behavioral Group Therapy + D-Cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT), Drug: D-Cycloserine | Arm Label: Cognitive Behavioral Group Therapy + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT), Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy (CBGT); Assigned to Arm(s): Cognitive Behavioral Group Therapy + D-Cycloserine, Cognitive Behavioral Group Therapy + Placebo | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): Cognitive Behavioral Group Therapy + D-Cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cognitive Behavioral Group Therapy + Placebo
D: Arm Label: D-cycloserine plus CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cycloserine, Behavioral: CBT | Arm Label: Placebo plus CBT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo pill, Behavioral: CBT | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus CBT | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Placebo plus CBT | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): D-cycloserine plus CBT, Placebo plus CBT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Antimicrobial Use and Time of Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction (PCR) in Real Time Multiplex to the Conventional Blood Culture for Etiologic Agents Identification. Randomized Clinical Trial.
Brief Summary: The objective of this study is to evaluate the consumption of antimicrobial therapy in patients comparing a rapid molecular test (PCR in Real-Time Multiplex) with blood cultures to identify the etiological agents of sepsis.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: detection of microbial DNA in blood by blood culture | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Detection of microbial DNA in blood by SeptiFast® | Intervention Type: OTHER; Name: Detection of microbial DNA in blood by SeptiFast®; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: detection of microbial DNA in blood by blood culture; Assigned to Arm(s): 2
B: Arm Label: Pathogen detection by Multiplex PCR; Type: ACTIVE_COMPARATOR; Interventions: Other: Antibiotic regimen | Arm Label: Pathogen detection by blood culture; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Antibiotic regimen; Assigned to Arm(s): Pathogen detection by Multiplex PCR
C: Arm Label: Standard blood culture and AST; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard Culture and AST | Arm Label: Rapid organism identification and AST; Type: ACTIVE_COMPARATOR; Interventions: Device: Accelerate PhenoTest™ BC Kit | Intervention Type: DEVICE; Name: Accelerate PhenoTest™ BC Kit; Assigned to Arm(s): Rapid organism identification and AST | Intervention Type: DEVICE; Name: Standard Culture and AST; Assigned to Arm(s): Standard blood culture and AST
D: Arm Label: betaLACTA® result given to physician; Type: EXPERIMENTAL; Interventions: Device: betaLACTA® rapid diagnostic test | Arm Label: betaLACTA® result NOT given to physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: betaLACTA® rapid diagnostic test; Assigned to Arm(s): betaLACTA® result given to physician

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme
Brief Summary: This is a multi-centre prospective, non-inferiority trial. Patients will be randomized to two treatment groups in a 1:1 ratio and will be stratified by age, Karnofsky Performance Status and extent of the surgical resection.

This study will assess the effect of a one-week radiotherapy regimen in comparison with a three-week radiotherapy regimen on the survival of elderly and/or frail patients with glioblastoma multiforme (Frail: ≥\>50 years old and with a KPS of 50% or less50%-70%; Elderly and frail: ≥65 years and with a KPS of 50% - 70%; Elderly: ≥65 years and with a KPS of 80% - 100%).


Options:
A: Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy
B: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation
C: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy of the partial brain. | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: Radiotherapy of the partial brain.; Assigned to Arm(s): Radiotherapy
D: Arm Label: Cilengitide + Temozolomide + Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cilengitide, Drug: Temozolomide, Radiation: Radiotherapy | Arm Label: Temozolomide + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cilengitide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme
Brief Summary: This is a multi-centre prospective, non-inferiority trial. Patients will be randomized to two treatment groups in a 1:1 ratio and will be stratified by age, Karnofsky Performance Status and extent of the surgical resection.

This study will assess the effect of a one-week radiotherapy regimen in comparison with a three-week radiotherapy regimen on the survival of elderly and/or frail patients with glioblastoma multiforme (Frail: ≥\>50 years old and with a KPS of 50% or less50%-70%; Elderly and frail: ≥65 years and with a KPS of 50% - 70%; Elderly: ≥65 years and with a KPS of 80% - 100%).


Options:
A: Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy
B: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy of the partial brain. | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: Radiotherapy of the partial brain.; Assigned to Arm(s): Radiotherapy
C: Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Arm Label: Radiation therapy (RT) alone; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: Intensive pre-treatment chemotherapy and radiation therapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy, Radiation therapy (RT) alone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Observational Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Dialysis Patients, in Conjunction With Standardized Care of Treatment
Brief Summary: A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM". However, it is also referred to as enteric toxin reduction technology. Our hypothesis is to assess the potential benefits in devising a bowel-based probiotic formulation (Kibow® Biotics/RenadylTM) as a dietary supplement product for patients undergoing dialysis along with standardized care of treatment.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cornstarch | Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Cornstarch; Assigned to Arm(s): Placebo
B: Arm Label: HSCB, Brooklyn, NY; Type: N/A; Interventions: N/A | Arm Label: 2. Nephrology Associates,; Type: N/A; Interventions: N/A | Arm Label: 3.New York Harbor VA Medical Center; Type: N/A; Interventions: N/A | Arm Label: 4.Hospital Juarez De Mexico; Type: N/A; Interventions: N/A | Arm Label: 5. Hospital Italiano de Buenos Aires; Type: N/A; Interventions: N/A | Arm Label: 6. National Hospital; Type: N/A; Interventions: N/A
C: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic
D: Arm Label: Dialysis patients; Type: N/A; Interventions: Dietary Supplement: Kibow Biotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Kibow Biotics; Assigned to Arm(s): Dialysis patients

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotic Prophylaxis for Urinary Tract Infection in Patients Requiring Catheterization After Urogynecologic Surgery
Brief Summary: This is a study of patients undergoing gynecologic surgery who require post-operative catheterization to determine if prophylactic antibiotic treatment decreases the risk of post-operative urinary tract infection in these patients.


Options:
A: Arm Label: Dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Mechanical Bowel Prep; Type: ACTIVE_COMPARATOR; Interventions: Other: Mechanical Bowel Prep | Arm Label: No Mechanical Bowel Prep.; Type: ACTIVE_COMPARATOR; Interventions: Other: No Mechanical Bowel Prep | Intervention Type: OTHER; Name: Mechanical Bowel Prep; Assigned to Arm(s): Mechanical Bowel Prep | Intervention Type: OTHER; Name: No Mechanical Bowel Prep; Assigned to Arm(s): No Mechanical Bowel Prep.
D: Arm Label: PFMT group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercises | Arm Label: HE + PFM group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercises | Arm Label: HE group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercises | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercises | Intervention Type: OTHER; Name: Exercises; Assigned to Arm(s): Control, HE + PFM group, HE group, PFMT group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotic Prophylaxis for Urinary Tract Infection in Patients Requiring Catheterization After Urogynecologic Surgery
Brief Summary: This is a study of patients undergoing gynecologic surgery who require post-operative catheterization to determine if prophylactic antibiotic treatment decreases the risk of post-operative urinary tract infection in these patients.


Options:
A: Arm Label: BMI <30; Type: N/A; Interventions: N/A | Arm Label: BMI 30-39; Type: N/A; Interventions: N/A | Arm Label: BMI >40; Type: N/A; Interventions: N/A
B: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors
Brief Summary: The objective of this study is to assess the efficacy of certolizumab pegol (CZP) with methotrexate (MTX) compared with MTX-alone in patients with early-stage rheumatoid arthritis (RA) who are naive to MTX and have with poor prognostic factors, using inhibition of radiographically confirmed joint damage progression over a one-year period as a primary endpoint. Following a year of treatment with CZP plus MTX treatment, CZP will be discontinued, and the subjects will be monitored for one more year (the follow-up period) to investigate the sustainability of efficacy of CZP during the MTX monotherapy for exploratory purposes.


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: PBO + MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: methotrexate (MTX) | Arm Label: CZP + MTX; Type: EXPERIMENTAL; Interventions: Drug: CZP, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PBO + MTX | Intervention Type: DRUG; Name: CZP; Assigned to Arm(s): CZP + MTX | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): CZP + MTX, PBO + MTX
C: Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo
D: Arm Label: RAPID3 to assess response to Cimzia; Type: OTHER; Interventions: Biological: Certolizumab Pegol (CZP) | Arm Label: CDAI to assess response to Cimzia; Type: OTHER; Interventions: Biological: Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP); Assigned to Arm(s): CDAI to assess response to Cimzia, RAPID3 to assess response to Cimzia

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS
Brief Summary: The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons and their metabolism) over one year between people with MS treated with Polyphenon E at a dose of 400mg twice a day and people with MS treated with a matching sugar pill.


Options:
A: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
B: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
C: Arm Label: Polyphenon E 400mg twice a day; Type: EXPERIMENTAL; Interventions: Drug: Polyphenon E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Polyphenon E; Assigned to Arm(s): Polyphenon E 400mg twice a day | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: vitamin A, multiple sclerosis,; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A, Drug: Drug: placebo | Arm Label: placebo/Multiple Sclerosis; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A; Assigned to Arm(s): placebo/Multiple Sclerosis, vitamin A, multiple sclerosis, | Intervention Type: DRUG; Name: Drug: placebo; Assigned to Arm(s): vitamin A, multiple sclerosis,

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development of Positive Psychotherapy for Smoking Cessation
Brief Summary: The primary objective of this study is to test a manualized adaptation of positive psychotherapy (PPT) for smoking cessation (PPT-S). The investigators will conduct a preliminary randomized clinical trial (N = 80) to examine the feasibility, acceptability, and efficacy of PPT-S over 26 weeks of follow up in comparison to a standard smoking cessation treatment. Both treatments will be delivered in individual 6 sessions over 6 weeks, and will include provision of transdermal nicotine patch. The effect size estimates from this Stage 1b research will provide the foundation for a future application to conduct a large-scale, Stage II, randomized clinical trial.


Options:
A: Arm Label: Family Spirit Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Family Spirit Intervention | Arm Label: Optimized Standard Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Family Spirit Intervention; Assigned to Arm(s): Family Spirit Intervention
B: Arm Label: Positive psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Psychotherapy for smoking cessation, Drug: Nicotine polacrilex, Behavioral: Behavioral smoking cessation treatment | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Behavioral: Relaxation training, Behavioral: Behavioral smoking cessation treatment | Intervention Type: BEHAVIORAL; Name: Positive Psychotherapy for smoking cessation; Assigned to Arm(s): Positive psychotherapy | Intervention Type: DRUG; Name: Nicotine polacrilex; Assigned to Arm(s): Positive psychotherapy, Standard treatment | Intervention Type: BEHAVIORAL; Name: Relaxation training; Assigned to Arm(s): Standard treatment | Intervention Type: BEHAVIORAL; Name: Behavioral smoking cessation treatment; Assigned to Arm(s): Positive psychotherapy, Standard treatment
C: Arm Label: Behavioral Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Counseling | Arm Label: Self-help control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-help control | Intervention Type: BEHAVIORAL; Name: Behavioral Counseling; Assigned to Arm(s): Behavioral Counseling | Intervention Type: BEHAVIORAL; Name: Self-help control; Assigned to Arm(s): Self-help control
D: Arm Label: virtual reality exposure therapy (VRET); Type: EXPERIMENTAL; Interventions: Other: virtual reality exposure treatment | Arm Label: cognitive and behavioral approaches therapy without VRET; Type: EXPERIMENTAL; Interventions: Other: cognitive and behavioral approaches therapy | Intervention Type: OTHER; Name: virtual reality exposure treatment; Assigned to Arm(s): virtual reality exposure therapy (VRET) | Intervention Type: OTHER; Name: cognitive and behavioral approaches therapy; Assigned to Arm(s): cognitive and behavioral approaches therapy without VRET

Answer: B